First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Total Liabilities
Everything the company owes to creditors and other parties.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities turns positive
Q1 FY2026 total liabilities was $33.11M, compared with -$391.6M a year earlier.
Context
- Total liabilities amounted to 11.4% of total assets at the end of Q1 FY2026.
- Total liabilities increased in 1 of the last 2 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +108.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 43.06M USD
- Year-over-year change
- -14.4%
- 2-year CAGR
- +12.1%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 43.06M | -14.4% |
| FY2024 | 2024-12-31 | 50.3M | +46.8% |
| FY2023 | 2023-12-31 | 34.26M | — |
Total Liabilities vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 total liabilities of $33.11M is the 7th highest of the 10 companies compared; the peer median is $46.21M.
- Its year-over-year change of +108.5% is the highest of 9, against a peer median of +15.6%.
- Total liabilities amounts to 11.4% of total assets for TRAX, versus a peer median of 20.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $316.94M | -18.3% | -2.1% | 96.1% | |
| Mar 2026 | $146.35M | +48.3% | +145.8% | 36.6% | |
| Sep 2026 | $104.02M | +64.5% | +34.3% | 13.7% | |
| Mar 2026 | $55.07M | +1.9% | +0.2% | 27.7% | |
| Mar 2026 | $46.21M | -1.1% | +117.0% | 31.5% | |
| Mar 2026 | $38.51M | +49.2% | +29.7% | 20.3% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $33.11M | +108.5% | — | 11.4% |
| Jun 2026 | $23.43M | +29.3% | +2.4% | 9.8% | |
| Jun 2026 | $15.58M | — | — | 12.1% | |
CLYMClimb Bio, Inc. | Mar 2026 | $4.29M | -41.7% | +5.0% | 2.8% |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $46.21M | +15.6% | +17.4% | 20.3% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.